Search Results

Keywords: sativex

New UK guidelines recommend public insurance coverage for two GW Pharma cannabis medicines, plus a synthetic cannabinoid

New British guidelines for the first time recommend that two plant-based cannabis medicines – Sativex and Epidiolex – be covered through the United Kingdom’s National Health Service (NHS), a significant step that is likely to boost sales of both products. Health regulators also are recommending the NHS make available a synthetic cannabinoid known as nabilone. […]

Read More

Cannabis producer Canopy downsizes Latin America workforce as region struggles to generate revenue

One of the largest cannabis companies in the world, Canopy Growth, is restructuring its overseas operations by laying off 15% of its workforce in Latin America, reflecting the slow pace at which revenue-generating opportunities and regulatory structures are evolving in the region. Though the layoffs account for a tiny fraction of the Canadian producer’s global 3,850-person workforce, […]

Read More

Danish medical cannabis sales stall on supply, price issues

Denmark’s medical cannabis pilot program saw virtually no quarter-over-quarter growth in the first half of 2019, according to new Danish Health Authority data. Experts say the market was hampered by a combination of prohibitively priced imports and supply issues. In the second quarter, 1,844 cannabis prescriptions were redeemed by 1,045 patients under Denmark’s four-year medical […]

Read More

France appears ready to OK funding for a medical cannabis experiment with 3,000 patients

French lawmakers appear ready to approve legislation to bankroll a two-year medical cannabis trial program for 3,000 patients, a move that would give overseas companies the opportunity to export product to what could become one of Europe’s largest markets. Olivier Véran, deputy of the French National Assembly, submitted an amendment to the Social Security Financing Bill (Projet de […]

Read More

European Commission approves Epidiolex marketing authorization, GW Pharmaceuticals says

The European Commission granted marketing authorization to Epidyolex, the trade name in Europe for Epidiolex, GW Pharmaceuticals announced Monday. In June 2018, the U.S. Food and Drug Administration approved Epidiolex for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome in patients two years of age and older. The CBD-based medicine was greenlighted in Europe […]

Read More

Global Cannabis: Brazil

Milestones in the Medical Cannabis Program The National Sanitary Surveillance Agency regulated “compassionate use” imports in 2015.   Key Laws and Regulations RDC No. 17/2015 Portaria 344/1998   Market Data Since 2014, almost 10,000 authorizations were granted to individual patients, allowing them to import medical cannabis on a case-by-case basis, each for a period of […]

Read More

Global Cannabis: Australia

Milestones in the Medical Cannabis Program The first cultivation license was issued in 2018.   Key Laws and Regulations Narcotic Drugs Act of 1967 (and 2016 amendment) Therapeutic Goods Act of 1989 Therapeutic Goods Regulations of 1990 Special Access Scheme   Market Data Cumulative patient approvals topped 9,300 as of June. Though the number seems […]

Read More

Global Cannabis: Italy

Milestones in the Medical Cannabis Program Doctors could first recommend cannabis-derived medicine in 2006, but significant quantities weren’t prescribed until 2014.   Key Laws and Regulations Law: April 8, 1998, n. 94 Ordinance: July 18, 2006 Ministerial Decree: April 18, 2007 Ministerial Decree: Jan. 23, 2013   Market Data No centralized registry of patients exists. […]

Read More

Global Cannabis: Germany

Milestones in the Medical Cannabis Program Germany established the current regulatory framework for its medical cannabis program in March 2017. It replaced a more restrictive program that had been in place for years.   Key Laws and Regulations Amendment of the German Narcotic Law, implemented in March 2017 Narcotics Act Medicinal Products Act Pharmacy Law […]

Read More

Growing Momentum: Australia

Milestones in the Medical Cannabis Program The first cultivation license was issued in 2018.   Key Laws and Regulations Narcotic Drugs Act of 1967 (and 2016 amendment) Therapeutic Goods Act of 1989 Therapeutic Goods Regulations of 1990 Special Access Scheme   Market Data Cumulative patient approvals topped 9,300 as of June. Though the number seems […]

Read More

Growing Momentum: Germany

Milestones in the Medical Cannabis Program Germany established the current regulatory framework for its medical cannabis program in March 2017. It replaced a more restrictive program that had been in place for years.   Key Laws and Regulations Amendment of the German Narcotic Law, implemented in March 2017 Narcotics Act Medicinal Products Act Pharmacy Law […]

Read More